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Background: To review the outcomes following cetuximab therapy in patients with metastatic colorectal
cancer.
Methods: Relevant articles were reviewed from the published literature using the Medline database. The
search was performed using the keywords “colorectal cancer”, “cetuximab”, “liver metastases”, “liver
resection” and “hepatectomy”.
Results: Cetuximab was ﬁrst used in the palliative setting and an increase in response rates were seen,
however with no improvement in overall survival. Published data have observed that cetuximab may be
beneﬁcial as part of a down-staging programme. The addition of cetuximab to chemotherapy regimens in
patients with KRAS wild-type colorectal cancer has been shown to increase the response rates and the
number of patients being down-staged and offered potentially curative resection. The OPUS and CRYSTAL
trials observed good response rates following the addition of cetuximab but low resection rates. The
CELIM and POCHER studies reported higher resection rates due to better patient selection and study
design. However, the majority of published studies tend to report minimal surgical data and lack short-
and long-term outcomes.
Conclusion: The use of cetuximab to conventional chemotherapy regimens may improve the efﬁcacy of
down-staging programmes, leading to more patients being offered potentially curative resection.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Colorectal cancer is the third most common cancer worldwide,1
and approximately 25% of patients have distant metastatic disease
at the time of diagnosis. Overall, approximately 50% of patients will
develop metastases during the course of the disease, with the liver
being the most common site.2 Hepatic resection has become the
treatment modality of choice for resectable colorectal liver me-
tastases (CRLM) and is associated with long-term survival in these
patients.3e5 More recently, studies have reported successful down-
staging chemotherapy regimens and subsequent hepatic resection
of initially unresectable CRLM.6,7 The addition of biological agents,
such as Cetuximab to these chemotherapy regimens in the neo-
adjuvant setting is thought to improve tumour response ratesry and Pancreatic Surgery, E
oad, Nottingham NG7 2UH,
(D. Gomez), iain.cameron@
ciates Ltd. Published by Elsevier Ltand consequently the survival of patients with unresectable CRLM,
as well as increasing hepatic resection rates.
Cetuximab is a monoclonal immunoglobulin G1 antibody that
targets the epidermal growth factor receptor (EGFR); this gene is
up-regulated in 60e80% of colo-rectal cancer cases.8 The EGFR
signalling pathway is involved in processes critical to tumour
growth and progression, including angiogenesis, apoptosis inhibi-
tion, invasion, and metastatic spread.9,10 Cetuximab has a higher
afﬁnity than EGFR’s natural ligands such as EGF and transforming
growth factor-a, thereby inhibiting the effects of EGFR activation.
However, besides the detection of EGFR expression, mutation of the
KRAS gene is an important predictive marker of resistance to
cetuximab treatment. Studies have demonstrated that cetuximab
efﬁcacy is conﬁned only to tumours without the KRAS gene muta-
tion, i.e. KRAS wild-type tumours.11e15
Since Cunningham et al. showed an improved survival in pa-
tients with metastatic colorectal cancer following the addition of
cetuximab, various studies have reported the outcomes following
cetuximab therapy.16 This present systematic review focuses on
studies reporting the outcome of cetuximab in the treatment ofd. All rights reserved.
D. Gomez et al. / International Journal of Surgery 11 (2013) 507e513508
REVIEWmetastatic colorectal cancer, in particular, in the neo-adjuvant
setting to down-stage unresectable CRLM sufﬁciently to allow for
potentially curative resection.
2. Methods
An electronic search was performed of theMedline database for the period 2000
e present using the MeSH headings: “colorectal cancer”, “cetuximab”, “liver me-
tastases”, “liver resection” and “hepatectomy”. The search was limited to English
language publications and human subjects. All titles and abstracts were reviewed,
and appropriate papers further assessed. The reference sections of all papers
deemed appropriate were further reviewed to identify papers that may have been
initially missed.
Studies were included if they described the survival outcome following cetux-
imab in patients with metastatic colorectal cancer. Theminimal data set required for
inclusion was: patients with metastatic colorectal cancer treated with cetuximab;
documentation of survival; description of chemotherapy regimens and response
rate; and resection rates if available (Fig. 1). All series ﬁtting the search speciﬁcations
independent of the study population were included. Publications that included
other biological agents were excluded. Case reports, editorials, abstracts and reviews
were also excluded.
Following the initial search that identiﬁed 1236 studies, a total of 1003 studies
were excluded: case reports (n¼ 121); abstracts (n¼ 346); review articles (n¼ 256);
non-English publications (n¼ 165); and non-human studies (n¼ 115). Two hundred
and thirty three studies were retrieved and evaluated, of which 30 studies were
included in this review. The remaining 204 studies were excluded as they were case
reports (n ¼ 61); abstracts (n ¼ 78); review articles (n ¼ 36); and duplicated studies
(n ¼ 29).
3. Early experience of cetuximab
The initial experience with cetuximab in the treatment of
metastatic colorectal cancer patients was as a single agent. Overall,
studies (Table 1) have reported an average partial response in 8.0e
11.6% patients, with an overall survival of 6.1e12.3 months.10,17e19
There was also a signiﬁcantly better survival and quality of life in
patients treated with cetuximab compared to best supportive-
care.19
Following these promising results, investigators have since re-
ported the results of cetuximab as a combination therapy (Table 2).
In the BOND trial,16 the authors showed that metastatic colorectal
cancer patients receiving the combination therapy of cetuximab
with irinotecan had a signiﬁcantly higher response rates and
reduced tumour progression compared to patients treated with
cetuximab alone. In a randomised trial consisting of 1298 patients
with metastatic colorectal cancer refractory to ﬂuoropyrimidinePotential relevant studies identified 
and screened for retrieval n = 1236 
Studies retrieved for more detailed 
evaluation n = 233 
Studies included in review n = 30 
Studies excluded n = 1003 
   Case reports n = 121 
   Abstracts n = 346 
   Review articles n = 256 
   Non-English n = 165 
   Non-human n = 115 
Studies excluded n = 204 
   Case reports n = 61 
   Abstracts n = 78
   Duplicate series n = 29 
   Review articles n = 36 
Fig. 1. Diagram demonstrating studies included in this review following the search
criteria.and oxaliplatin treatment, Sobrereo et al.20 observed that cetux-
imab and irinotecan signiﬁcantly increased both the response rates
and progression-free survival compared to irinotecan alone.
Nevertheless, the overall survival in both the above studies did not
signiﬁcantly improve with the addition of cetuximab.16,20 The
COIN trial reported that although the addition of cetuximab to
oxaliplatin-based chemotherapy in ﬁrst-line treatment of patients
with advanced colorectal cancer increased the response rate, there
was no signiﬁcant beneﬁt with respect to progression-free or
overall survival compared to patients that received oxaliplatin-
based chemotherapy only.21 Other studies have reported similar
ﬁndings with respect to overall survival.22e25
The above published studies conﬁrm that the response rates in
patients with metastatic colorectal cancer that were refractory to
irinotecan and/or oxaliplatin-based regimens improved following
the addition of cetuximab,16,24,26e29 suggesting that resistance to
previous chemotherapy regimens are not a negative predictor for
response to cetuximab. Nevertheless, the increase in response rates
following combination therapy of cetuximab and chemotherapy
regimens is not translated into a signiﬁcant improvement in overall
survival, even in patients with KRASwild-typemetastatic colorectal
cancer, and hence its use in the palliative setting cannot be
recommended.
4. Cetuximab as part of a down-staging programme
Based on the above results, the addition of cetuximab does in-
crease the response rates compared to chemotherapy-only regi-
mens in metastatic colorectal cancer patients, but this does not
translate into improvement in survival rates. Hence, the role of
cetuximab has been explored in down-staging chemotherapy
programmes (Table 3), with the four landmark clinical trials known
as the OPUS,30 CRYSTAL,31 CELIM,32 and POCHER trials.33
4.1. Cetuximab with oxaliplatin-based chemotherapy
In the OPUS study,30 the authors reported an overall response
rate of 72% in 43 patients with metastatic colorectal cancer treated
with ﬁrst-line combination therapy of cetuximab and FOLFOX-4.
The median progression free and overall survival was 12.3 and
30.0 months, respectively. Ten patients (23%) that were deemed to
have unresectable disease were down-staged and underwent
potentially curative surgery, of which nine patients had R0 resec-
tion. Curative surgery included hepatic resection (n ¼ 8), lung
resection (n ¼ 1) and adrenalectomy (n ¼ 1).30 However, the au-
thors did not specify the type of liver resection performed or pro-
vide separate survival data for patients who underwent surgery
following down-staging therapy compared to patients that were
not operated on.
Arnold and colleagues34 observed a resectability rate of 8.2%
(n ¼ 4) following down-staging of CRLM with cetuximab and
oxaliplatin-based chemotherapy, of which an R0 resection was
achieved in 50% of cases. The median progression free and overall
survival was 8.1 and 28.2 months, respectively.34 However, this
study did not report type of liver resection and extent of disease
burden of patients that underwent liver resection.
4.2. Cetuximab with irinotecan- and/or oxaliplatin- based
chemotherapy
In the CRYSTAL study, Van Cutsem et al. investigated the efﬁcacy
of ﬁrst-line cetuximab with FOLFIRI compared to FOLFIRI alone in
patients with unresectable, metastatic colorectal cancer.31 Tumour
responses were seen in 281 (46.9%) patients receiving cetuximab
and FOLFIRI and in 232 (38.7%) patients receiving FOLFIRI alone. In
Table 1
Published studies on results of cetuximab mono-therapy on patients with metastatic colorectal cancer in the palliative setting.
Study (Centre) Study type Patient groups Response, n (%) Median overall
survival (months)
Complete Partial Stable Progression
Saltz et al. (2004),17 Multi-center, USA Phase II study Cetuximab ¼ 57 0 (0) 5 (8.8) 21 (36.8) 21 (36.8) 6.4
Lenz et al. (2006),10 Multi-centre Phase II study Cetuximab ¼ 346 0 (0) 40 (11.6) 110 (31.8) 160 (46.2) NR
Jonker et al. (2007),19 Multi-centre Randomised trial Cetuximab ¼ 287 0 (0) 23 (8.0) 90 (31.4) 224 (78.0) 6.1
Best supportive care ¼ 285 0 (0) 0 (0) 31 (10.9) 178 (62.5) 4.6
Pessino et al. (2008),18 2 centres, Italy Phase II study Cetuximab ¼ 39 1 (2.6) 3 (7.7) 13 (33.3) 22 (56.4) 12.3
NR ¼ Not reported.
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curative intent for metastases compared with 3.7% in the FOLFIRI
only group. The rate of R0 resection was also higher in the
cetuximab-FOLFIRI group (4.8%) compared to the FOLFIRI only
group (1.7%). However, no details with respect to surgery for met-
astatic disease and pattern of recurrence were reported. The me-
dian progression free and overall survival was 8.9 and 8.0 months;
and 19.9 months and 18.6 months; respectively in the cetuximab-
FOLFIRI group and FOLFIRI only group.31 This similarity in sur-
vival between treatment groups was likely to be secondary to post-
trial therapy (25.4% of patients in the FOLFIRI group and 6.2% in the
cetuximab-FOLFIRI group received EGFR antibody therapy post-
study). Raoul and co-investigators showed an overall response
rate of 48% and median duration of response of 9.9 months
following treatment with cetuximab combined with FOLFIRI.35 This
study also showed that the cetuximab combination therapy suc-
cessfully down-staged 14 (27%) patients that were deemed to have
inoperable disease prior to therapy, of which most had liver me-
tastases, 2% for lung and 4% for metastases at other sites. These
patients underwent surgery with curative intent and the R0Table 2
Published studies on results of cetuximab in combination with chemotherapy on patien
Study (Centre)a Study type Patient groups
Cunningham et al.16
(2004), 56 centres
Randomised trial Cetuximab þ Irinotecan ¼ 218
Cetuximab ¼ 111
Vincenzi et al.25 (2006), Italy Phase II study Cetuximab þ Irinotecan ¼ 55
Meyerhardt et al.43
(2006), USA
Retrospective study Cetuximab þ Irinotecan ¼ 20
Cetuximab ¼ 4
Souglakos et al.28
(2007), Greece
Phase II study Cetuximab, Capecitabine þ Oxal
Koo et al. (2007),23
South Korea
Phase II study Cetuximab þ FOLFIRI ¼ 31
Pfeiffer et al. (2007),44
3 centres Denmark
Case controlled study Cetuximab þ Irinotecan ¼ 65
Pfeiffer et al. (2008),22
2 centres Denmark
Case controlled study Cetuximab þ Irinotecan ¼ 74
Martín-Martorel et al.
(2008),45 Spain
Phase II study Cetuximab þ Irinotecan ¼ 39
Wilke et al. (2008),24
197 centres
Non-randomised study Cetuximab þ Irinotecan ¼ 93
Cetuximab þ 2 weekly Irinoteca
Cetuximab þ 3 weekly Irinoteca
Cetuximab þ other Irinotecan ¼
All patients ¼ 1147
Sobrero et al. (2008),20
221 centres
Randomised trial Cetuximab þ Irinotecan ¼ 648
Irinotecan ¼ 650
Ocvirk et al. (2010),29
28 centres
Randomised trial Cetuximab þ FOLFOX6 ¼ 74
Cetuximab þ FOLFIRI ¼ 77
Lim et al. (2011),26
25 centres
Phase II study Cetuximab þ Irinotecan ¼ 123
Maughan et al. (2011),21
Multi-centres
Randomised trial Oxaliplatin þ Capecitabine or FU
Cetuximab þ Oxaliplatin,Capeci
NR ¼ Not reported; FOLFOX ¼ Folinic acid, Fluorouracil, Oxaliplatin; FOLFIRI ¼ Folinic ac
a: Single centre unless otherwise stated. b: Survival data presented as median (95% con
b: Results here represent patients with a complete or partial response in KRAS wild-typeresection rate was 71% (n ¼ 10) of cases.35 The median overall
survival was 22.4 months in the whole cohort.35 No further details
with regards to post-operative morbidity and survival were
reported.
In another randomised study assessing the combination therapy
of cetuximab with or without the FOLFOX-4 regimen, Bokemeyer
et al. reported a better overall response rate in the cetuximab and
FOLFOX-4 group compared to the FOLFOX-4 only group with no
difference in median progression-free survival.36 Cetuximab com-
bination therapy doubled the R0 resectability rate (n ¼ 6, 9.8%
versus n¼ 3, 4.1%) compared to chemotherapy only in patients with
KRAS wild-type tumours.36 The authors did not report details
regarding surgery following down-staging treatment, and survival
outcome.36
Borner and co-investigators randomised 74 patients with met-
astatic colorectal cancer to ﬁrst-line treatment with oxaliplatin and
capecitabine (XELOX) alone or in combination with cetuximab.37
The median overall survival was 16.5 months and 20.5 months in
the XELOX only group and in the XELOX and cetuximab group,
respectively. Four out of ten patients in the XELOX group and fourts with metastatic colorectal cancer in the palliative setting.
Response, n (%) Overall survivalb
Complete Partial Stable Progression
0 (0) 50 (22.9) 71 (32.6) 68 (31.2) 8.6
0 (0) 12 (10.8) 24 (21.6) 59 (53.2) 6.9
0 (0) 14 (25.4) 21 (38.2) 19 (34.4) 9.8 (3.9e10.1)
0 (0) 3 (12.5) 13 (54.2) 6 (25.0) NR
iplatin ¼ 40 1 (2.5) 7 (17.5) 11 (27.5) 21 (52.5) 10.7
0 (0) 8 (25.8) 10 (32.3) 11 (35.5) 10.9 (3.8e18.0)
0 (0) 12 (18.5) 31 (47.7) 15 (23.1) 10.4 (7.2e13.1)
1 (1.4) 18 (24.3) 38 (51.4) 13 (17.6) 8.9 (7.0e10.5)
2 (5.1) 7 (17.9) 15 (37.5) 15 (37.5) 8.0
1 (1.1) 16 (17.2) 23 (24.7) 45 (48.4) 8.3 (6.9e11.3)
n ¼ 670 1 (0.1) 16 (17.2) 159 (23.7) 340 (50.7) 9.2 (8.4e9.8)
n ¼ 356 0 (0) 92 (25.8) 99 (27.8) 134 (37.6) 10.3 (8.7e11.3)
28 1 (3.6) 5 (17.9) 7 (25.0) 9 (32.1) 7 (4.6e10.2)
3 (0.3) 228 (19.9) 288 (25.1) 528 (46.0) 9.2 (8.6e9.8)
9 (1.4) 97 (15.0) 292 (45.1) 174 (26.9) 10.7 (9.6e11.3)
1 (0.2) 26 (4.0) 271 (41.7) 243 (37.4) 10 (9.1e11.3)
2 (2.7) 31 (41.9) 31 (41.9) 6 (8.1) 17.4 (14.9e22.6)
6 (7.8) 27 (35.1) 24 (31.2) 9 (11.7) 18.9 (14.7e23.9)
1 (0.8) 16 (13.0) 44 (35.8) 52 (42.3) 9.5 (7.5e11.7)
¼ 815 209 (57.0)b NR NR 17.9 (10.3e29.2)
tabine/FU ¼ 815 232 (64.0)b NR NR 17.0 (9.4e30.1)
id, Fluorouracil, Irinotecan.
ﬁdence interval) months where available.
patients in the control group and cetuximab group.
Table 3
Published studies on results of cetuximab on down-staging disease in patients with metastatic colorectal cancer.
Study (Centre)a Study
type
Patient groups Response, n (%) Resection rate:
n(%)c [R0 ¼ n]
Overall survivalb
Complete Partial Stable Progression
Folprecht et al. (2006),46
3 centres, Germany
Phase I/
II trial
Cetuximab þ Irinotecan, FA,
low dose 5-FU ¼ 6
1 (16.7) 3 (50.0) 2 (33.3) 0 (0) 4(19) [4] 33 (20 e not
reached)
Cetuximab þ Irinotecan, FA,
high dose 5-FU ¼ 15
1 (6.7) 9 (60.0) 4 (26.7) 1 (6.7)
All ¼ 21 2 (9.5) 12 (57.1) 6 (28.6) 1 (4.8)
Tabernero et al. (2007),30
Multi-centre
Phase
II trial
Cetuximab þ FOLFOX-4 ¼ 43 4 (9.3) 27 (62.8) 10 (23.3) 1 (2.3) 10 (23.2)d [9] 30 (17.8e33.8)
Adam et al. (2007),47 France Case
series
Cetuximab þ Irinotecan or
Oxaliplatin ¼ 151
0 (0) 23 (15.2) 4 (2.6) 0 (0) 25 (16.6) [10] 20 (NR)
Borner et al. (2008),37
Multi-centre
RCT Capecitabine þ Oxaliplatin ¼ 37 0 (0) 5 (13.5) 23 (62.1) 6 (16.2) 4/10e 16.5 (14.3e27.0)
Cetuximab þ Capecitabine þ
Oxaliplatin ¼ 37
0 (0) 15 (40.5) 13 (35.1) 7 (18.9) 4/14e 20.5 (15.5e27.2)
Arnold et al. (2008),34
Multi-centre
Phase Ib/
II trial
Cetuximab þ Oxaliplatin, FA,
low dose 5-FU ¼ 8
0 (0) 5 (62.5) 1 (12.5) 1 (12.5) 4 (8.2) [2] 28.2 (14.7enot
reached)
Cetuximab þ Oxaliplatin, FA,
high dose 5-FU ¼ 41
1 (2.4) 22 (53.7) 9 (22.0) 6 (14.6)
All ¼ 49 1 (2.0) 27 (55.1) 10 (20.4) 7 (14.3)
Van Custem et al. (2009),31
Multi-centre
RCT Cetuximab þ FOLFIRI ¼ 599 3 (0.5) 278 (46.4) 224 (37.4) NR 7.0% (R0 ¼ 4.8%) 19.9 (18.5e21.3)
FOLFIRI ¼ 599 2 (0.3) 230 (38.4) 280 (46.7) NR 3.7% (R0 ¼ 1.7%)f 18.6 (16.6e19.8)
Bokemeyer et al. (2009),36
79 centres
RCT FOLFOX-4 ¼ 168 1 (0.6) 59 (35.1) 76 (45.2) 21 (12.5) [R0 ¼ 3 of 73, NR
Cetuximab þ FOLFOX-4 ¼ 169 2 (1.2) 75 (44.4) 67 (39.6) 18 (10.7) R0 ¼ 6 of 61]g NR
Raoul et al. (2009),35
Multi-centre
Phase I/
II study
FOLFIRI þ Cetuximab
(low dose 5-FU) ¼ 7
0 (0) 0 (0) 2 (28.7) 1 (14.3) 18.1 (8.7e24.9)
FOLFIRI þ Cetuximab
(high dose 5-FU) ¼ 45
0 (0) 0 (0) 18 (40.0) 4 (8.9) 22.6 (16.5e25.6)
All ¼ 52 0 (0) 0 (0) 20 (38.5) 5 (9.6) 14 (26.9)h [71%] 22.4 (16.5e24.9)
Buzaid et al. (2010),27
Multi-centre
Phase
II trial
Cetuximab þ Irinotecan ¼ 79 1 (1.3) 20 (25.3) 23 (29.1) 30 (38.0) 2 (2.5)i [NR] 9.2 (7.9e10.8)
Garuﬁ et al. (2010),33
2 centres, Italy
Phase
II trial
Cetuximab þ chrono-chemotherapy
(Irinotecan, 5-FU,
leucovorin þ Oxaliplatin) ¼ 43
0 (0) 34 (79.1) 5 (11.6) NR 26 (60.5) [R0 ¼ 60%] 37.0 (21.0e53.0)
Brouquet et al. (2010),48 USA Retro-
spective
5-FU, Irinotecan þ Bevacizumab or
Cetuximab in 42/60 (70%) ¼ 60
1 (1.7) 21 (35.0) 22 (36.7) 16 (26.7) 60 (100) [48] 5 year: 22%
Folprecht et al. (2010),32
Multi-centre
RCT Cetuximab þ FOLFOX6 ¼ 53 0 (0) 36 (67.9) 15 (28.3) 2 (3.8) 22 (41.5%) [20] NR
Cetuximab þ FOLFIRI ¼ 53 0 (0) 30 (56.6) 16 (30.2) 7 (13.2) 23 (43.4%) [16]
Lévi et al. (2011),41 France Case
series
Cetuximab, 5-FU þ Irinotecan
(61%), Oxaliplatin
(25%) or both (14%) ¼ 53
3 (5.6) 14 (26.4) 18 (34.0) 18 (34.0) 11 (20.8%)j [9] 13.7 (8.1e19.2)
RCT ¼ Randomised controlled trial; NR ¼ Not reported; FA ¼ Folinic acid; FU ¼ Fluorouracil; FOLFOX ¼ Folinic acid, Fluorouracil, Oxaliplatin; FOLFIRI ¼ Folinic acid, Fluo-
rouracil, Irinotecan.
a Single centre unless otherwise stated.
b Survival data presented as median (95% conﬁdence interval) months where available.
c Liver resection rate reported unless otherwise stated.
d 10 (23%) patients had surgery; liver surgery (n ¼ 8), lung surgery (n ¼ 1) and adrenal surgery (n ¼ 1).
e 4 out of 10 and 4 out of 14 patients were suitable for liver resection following down-staging of CRLM.
f Surgical results presented as percentages, with no further details of surgery reported.
g Cetuximab doubled the R0 resection rate in patients that were KRAS wild-type tumour.
h 14 patients had surgery: liver resection (21%), lung resection (2%) and other sites (4%). The R0 resection rate was presented as a percentage.
i No surgical details given.
j Nine patients had R0 resection: liver resection (n ¼ 4), lung surgery (n ¼ 3), lymph node resection (n ¼ 1) and pelvic recurrence resection (n ¼ 1).
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conﬁned to the liver that was down-staged and suitable for liver
resection. However, no details of hepatic resection were reported.
Folprecht and co-workers conducted amulti-centre randomised
(CELIM) study to assess the efﬁcacy of cetuximab in different
chemotherapy regimens (FOLFOX-6 versus FOLFIRI) in the treat-
ment of 106 patients with technically non-resectable or ﬁve or
more CRLM.32 A total of 45 (42.4%) patients underwent liver
resection, of which 22 (41.5%) patients were from the cetuximab-
FOLFOX-6 group and 23 (43.4%) patients were from the
cetuximab-FOLFIRI group. The overall R0 resection rate was 34%
(n ¼ 36) [cetuximab-FOLFOX-6 ¼ 20 (38%) and cetuximab-
FOLFIRI ¼ 16 (30%)]. Although this study reported signiﬁcantly
better down-staging of CRLM with the addition of cetuximab to
conventional chemotherapy, details of type of liver resection, post-
surgical outcomes and survival data were not reported.4.3. Cetuximab with chrono-modulated chemotherapy
More recently, two studies have shown promising outcomes
following the combination of cetuximab with chrono-modulated
chemotherapy regimens. Previous studies have suggested
improved efﬁcacy of chrono-modulated chemotherapy compared
to constant rate infusion chemotherapy for ﬁrst-line treatment of
patients withmetastatic colorectal cancer.38e40 In the POCHER trial,
Garuﬁ et al.33 evaluated the rate of CRLM resection in 43 patients
with unresectable metastatic colorectal cancer following treatment
with cetuximab and chrono-modulated chemotherapy which
consisted of irinotecan, 5-ﬂuorouracil, leucovorin and oxaliplatin.
This study reported an overall response rate of 79.1%, and 26
(60.5%) patients underwent liver resection with an R0 resection
rate of 60%: multiple metastectomies (n ¼ 13); two-stage hepa-
tectomy (n ¼ 9); right hepatectomy (n ¼ 3) and left hepatectomy
D. Gomez et al. / International Journal of Surgery 11 (2013) 507e513 511
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patient had both liver and lung resection, while one patient had
disease progression following liver resection and two patients did
not have surgery. The median time from discontinuation of
chemotherapy to surgery was 5 weeks (range: 1e11). The 2-year
survival was signiﬁcantly better in patients that had surgery
(80.6%) compared to unresected patients (47.1%). Twenty patients
had disease recurrence following liver resection [intra-hepatic
(n ¼ 10, 38%); extra-hepatic (n ¼ 4, 15%) and both intra- and ex-
tra- hepatic (n ¼ 6, 23%)]. Five patients with isolated liver re-
currences had repeat hepatectomy. The median time from surgery
until relapse was 11 months.33
Lévi and co-workers observed promising results following
cetuximab and circadian-based chrono-modulated chemotherapy
(irinotecan, oxaliplatin, 5-ﬂuorouracil and leucovorin) in 53 pa-
tients with advanced metastatic colorectal cancer who had disease
progression on at least one prior chemotherapy regimen.41 The
objective response rate was 36% and nine (17.0%) patients under-
went R0 resection [liver (n ¼ 4); lung (n ¼ 3); lymph node (n ¼ 1);
and pelvic (n ¼ 1) disease] and two patients underwent R1 liver
resection. The median progression-free and overall survival was 4.6
and 13.7 months, respectively. The median relapse-free survival for
these 11 surgically treated patients was 10.0 months.5. Discussion
Currently, randomised trials have shown that the addition of
cetuximab to irinotecan- or oxaliplatin- based chemotherapy reg-
imens increased tumour response and down-staging of initially
unresectable disease, leading to an increased resection rate for
metastases compared to conventional chemotherapy regimens. The
role of cetuximab in down-staging of metastatic disease has led to
clinical “controversies” with respect to patient selection, pre-
operative staging, response rates and resection rates. In addition,
the cost of cetuximab and other secondary costs also need to be
taken into account.
Folprecht et al. analysed published or presented trials and
retrospective studies that reported the rate of objective response
following neo-adjuvant chemotherapy and the resection rates of
initially unresectable metastases to correlate objective response
and the rate of resection of colorectal metastases.42 The authors
reported a resection rate of 24e54% following chemotherapy in
patients with CRLM only, compared to 1e26% of patients in trials
that included non-selected patients with metastatic colorectal
cancer. A signiﬁcant correlation was found between response rates
and resection rates in studies that included patients with liver-
limited disease, and the authors showed that with a response
rate of approximately 70%, a resection rate of around 50% can be
expected.42 This emphasises that the main end-point of down-
staging chemotherapy in CRLM patients is to achieve potentially
curative liver resection and long-term survival.Table 4
Differences between the main published studies on results of cetuximab on down-stagin
Study (Name) Patient recruitment Overall response rates w
Tabernero et al. (OPUS)30 General oncologist 72.0
Van Custem et al. (CRYSTAL)31 General oncologist 46.9
Folprecht et al. (CELIM)32 MDT with Liver surgeon 62.3
Garuﬁ et al. (POCHER)33 MDT with Liver surgeon 79.1
MDT ¼ Multi-Disciplinary Team Meeting.
a Liver resection rate reported as percentage of overall response rate.
b 10 (23%) patients had surgery; liver surgery (n ¼ 8), lung surgery (n ¼ 1) and adren
c Surgical results presented as percentages, with no further details of surgery reporteTo achieve an appropriate resection rate following neo-adjuvant
therapy, patient selection and efﬁcacy of therapy are both important
predictors for resectability of CRLM. The majority of current pub-
lished studies with respect to cetuximab have not clearly stated
their selection criteria or deﬁned non-resectability. There is
currently no standard deﬁnition of non-resectable or borderline
disease, and hence this has an impact on patient selection for down-
staging therapy. Both the CRYSTAL and OPUS trial observed an
overall response rate of 46.9% and 72%. In addition, the CRYSTAL trial
showed an increase in the resection rate from 3.7% to 7.0% following
the addition of cetuximab to FOLFIRI,31 while the OPUS trial re-
ported that the addition of cetuximab to FOLFOX doubled the rate of
liver resection from 2.4% to 4.7%.36 Although both trials noted a
higher R0 resection rate with the addition of cetuximab therapy, no
details with respect to type of surgery and survival outcome were
reported.31,36 Although both these trials did report better response
rates following the addition of cetuximab to conventional chemo-
therapy, the resection rates were still less than 10%. As previously
reported by Folprecht and co-workers,42 resection rates of 1e26%
following chemotherapywas achieved in studies that included non-
selected patients with metastatic colorectal cancer. Both the CRYS-
TAL and OPUS trials observed this ﬁnding, as patients with multiple
metastatic sites were included, which were mainly designed to
identify the efﬁcacy and tolerability of newcetuximab regimens and
secondary resection was probably reported as an incidental obser-
vation. In addition, disease resectability in these patients was
determined by general oncologist, rather than liver surgeons.
In contrast, the CELIM study reported resection rates of 38%with
the combination of cetuximab and FOLFOX and 30% with cetux-
imab and FOLFIRI following a response rate of 67.9% and 56.6%,
respectively.32 However, patients included in this trial had liver-
limited (technically non-resectable or 5 liver metastases) dis-
ease. The authors also noted a signiﬁcantly better response in pa-
tients with KRAS wild-type tumours (70%) compared to patients
with KRAS-mutated tumours (41%). Of note, in a retrospective re-
view, the authors blinded eight liver surgeons to review the com-
puter tomography scans following down-staging; and although
there was some disagreement regarding resectability, there was a
general consensus that resectability rates increased signiﬁcantly
from 32% to 60% after neo-adjuvant therapy. In the POCHER trial,
Garuﬁ et al. observed a 60.5% liver resection rate following neo-
adjuvant therapy (cetuximab and chrono-modulated irinotecan,
5-ﬂuorouracil, leucovorin and oxaliplatin) that resulted in a 79.1%
response rate.33 The authors showed a signiﬁcantly better 2-year
survival of 80.6% following liver resection compared to 47.1% in
patients with unresectable disease.
The higher resection rates observed in both the CELIM32 and
POCHER33 trials were likely to be inﬂuenced by patient selection
and study design. These trials included patients with liver-limited
disease and a high proportion of patients with KRAS wild-type tu-
mours, of which cetuximab is more effective. In addition, chrono-
modulated chemotherapy with cetuximab produced a higherg disease in patients with metastatic colorectal cancer.
ith cetuximab (%) Decision on resectability Resection rate: n(%)a [R0 ¼ n]
General oncologist 10 (23.2%)b [R0 ¼ 9]
General oncologist 7.0% [R0 ¼ 4.8%]c
MDT with Liver surgeon 45 (34.0%) [R0 ¼ 36]
MDT with Liver surgeon 26 (60.5) [R0 ¼ 60%]
al surgery (n ¼ 1).
d.
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REVIEWresponse rate and resection rates33,41 Both these trials speciﬁcally
selected patients into a down-staging regimen and their primary
outcome was to assess the resectability rates. Patients were
recruited as part of a multi-disciplinary meeting that included liver
surgeons, and resectability was determined by liver surgeons
(Table 4). Both the results of CELIM and POCHER trials are in
keeping with the analysis by Folprecht et al.42
To enable these results to be replicated in other centres, down-
staging trials need to be designed with strict selection criteria for
patients that can be potentially down-staged for liver and/or lung
resection. In addition, all patients included in such trials need to be
managed by specialist inter-disciplinary teams, that includes on-
cologists, radiologist and liver surgeons with an interest in meta-
static colorectal cancer. It cannot be stressed enough the
importance of these multi-disciplinary teams meetings are, in
particular, in patients with metastatic colorectal cancer. These
meetings assist in determining the type and duration of neo-
adjuvant chemotherapy as well as an objective assessment of
down-staging. The duration of neo-adjuvant therapy should be
based on tumour shrinkage sufﬁcient to allow R0 liver resection,
rather than to achieve complete response.
Nevertheless, the majority of published studies with cetuximab
therapy tend to report minimal surgical data and lack details
regarding unresectability. Following down-staging of disease, most
studies did not report the type of liver surgery undertaken or the
post-operative outcomes. Although most studies showed an
improved responsewith the addition of cetuximab, the reporting of
overall survival in the sub-group of patients that underwent liver
resection following neo-adjuvant cetuximab therapy was limited.6. Conclusion
In summary, cetuximab may be beneﬁcial in down-staging
programmes for patients with metastatic colorectal cancer. How-
ever, these early promising results require further appraisal. In the
down-staging setting, resectability following neo-adjuvant cetux-
imab and chemotherapy is a distinct end-point from the more
classical end-points of response rates, progression-free survival or
median survival. More trials managed by specialist inter-
disciplinary teams are required, with the aim to deﬁne which pa-
tients are likely to beneﬁt from the more aggressive approach of
neo-adjuvant cetuximab and subsequent resection. Further long-
term outcome following this down-stage programme is clearly
the next step to be evaluated.
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